2020
August
cDC1s take on double duty, priming both CD8+ and CD4+ T cells
August 26, 2020
In the currently understood paradigm of T cell priming, it has generally been assumed that cDC1s cross-present peptides on MHC-I to prime CD8+ T cells, while cDC2s, which express high levels of MHC-II, present antigens on MHC-II to prime CD4+ T cells. CD4+ T cells are then thought to license cDC1s, supporting CD8+...
Remodeling tumor macrophages for effective checkpoint blockade therapy
August 19, 2020
While immune checkpoint therapy (ICT) has successfully treated a wide array of cancers, the majority of patients do not benefit. This may, in part, be due to immune suppression within the tumor microenvironment (TME), relying on certain myeloid cell populations that can dampen T cell immunity and aid tumor progression. In work recently...
RNA vaccine for melanoma shows promise in early clinical trial
August 12, 2020
In the world of cancer vaccines, targeting tumor-associated antigens (TAAs) has historically yielded only weak immune responses. In an effort to improve vaccine targeting of TAAs, researchers developed a nanoparticulate liposomal RNA (RNA-LPX) that targeted dendritic cells in vivo and induced antigen presentation on HLA-I and HLA-II molecules in lymphoid compartments in mice...
